BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1226 related articles for article (PubMed ID: 25471252)

  • 21. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder.
    Castagnola E; Moresco L; Cappelli B; Cuzzubbo D; Moroni C; Lanino E; Faraci M
    J Chemother; 2007 Jun; 19(3):339-42. PubMed ID: 17594932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.
    Krüger W; Stockschläder M; Sobottka I; Betker R; De Wit M; Kröger N; Grimm J; Arland M; Fiedler W; Erttmann R; Zander AR
    Leuk Lymphoma; 1997 Feb; 24(5-6):491-9. PubMed ID: 9086439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
    Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
    Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
    Sun HY; Cacciarelli TV; Singh N
    Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.
    Monforte V; Ussetti P; Gavaldà J; Bravo C; Laporta R; Len O; García-Gallo CL; Tenorio L; Solé J; Román A
    J Heart Lung Transplant; 2010 May; 29(5):523-30. PubMed ID: 20061165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of liposomal amphotericin B in bone marrow transplant.
    Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
    J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
    Girmenia C; Iori AP
    Expert Opin Drug Saf; 2017 Mar; 16(3):329-339. PubMed ID: 28004589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
    Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.